Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Ibrutinib dosing changes and the impact on survival

Williams AM et al. Clin Lymphoma Myeloma Leuk. 2018 Oct 12. doi: 10.1016/j.clml.2018.10.005

Key clinical point: Early dose reductions and discontinuation of ibrutinib is linked to inferior progression-free survival in non-Hodgkin lymphoma.

Major finding: Median overall survival after discontinuation of ibrutinib due to disease progression was 1.7 months.

Study details: A single-institution study of 170 patients with CLL or non-Hodgkin lymphoma who were taking ibrutinib.

Disclosures: The study was funded by the National Cancer Institute and the Cadregari Endowment Fund. The researchers reported having no conflicts of interest.

Read the article here.

Citation:

Williams AM et al. Clin Lymphoma Myeloma Leuk. 2018 Oct 12. doi: 10.1016/j.clml.2018.10.005.